News

Abbey Kaler, MS, APRN, FNP-C, CMSRN, demonstrated extraordinary oncology nursing by being a consistent champion of the patient’s voice.

Enfortumab vedotin plus pembrolizumab elicited durable responses in patients with locally advanced or metastatic urothelial carcinoma who were ineligible for cisplatin.

Novel strategies for patient education can help to build trust in and decrease the fear of lung cancer screening among patients.

Meredith Cummings, BSN, RN, OCN, discusses the potential benefit of machine learning in predicting symptoms for patients with head and neck cancer.

According to investigators, digitized cognitive behavioral stress management may help clinicians offer more comprehensive cancer care.

Sacituzumab govitecan improved overall survival vs treatment of physician’s choice in pretreated, endocrine-resistant, hormone receptor–positive, HER2-negative metastatic breast cancer.

Ciltacabtagene autoleucel improved progression-free survival vs pomalidomide, bortezomib, and dexamethasone or daratumumab, pomalidomide, and dexamethasone in patients with lenalidomide-refractory multiple myeloma.

Kara Morris, MSN, RN, OCN; and Christine Wylie, MSN, RN, OCN, discuss their research on oral cryotherapy as a mucositis mitigation strategy.

Debi Fischer, MSW, BSN, BA, LCSW, RN, walks through some cancer support groups that may be of interest to oncology specialists.

Shivani Gopalsami, RN, MSN, ANP-BC, AOCNP; and Tia Wheatley, DNP, RN, AOCNS, BMTCN, highlight the value of multidisciplinary approaches in hematopoietic stem cell transplantation care.

Phase 2 findings show that adding a tyrosine kinase inhibitor to dual immunotherapy curbed disease progression in patients with metastatic soft tissue sarcoma.

Numerical, but not statistically significant, improvements in survival were observed in patients with TKI-resistant, EGFR-mutated, metastatic nonsquamous non–small cell lung cancer who received pembrolizumab to pemetrexed and platinum-based chemotherapy.

Yelena Shames, MSA, ACNP-BC, CNRN, argues that frequent hematologic evaluations may not always be warranted with immune checkpoint inhibitors.

Sintilimab plus chemoradiotherapy was associated with better event-free survival rates in locally advanced nasopharyngeal carcinoma than chemoradiotherapy alone.

A 5-year analysis of the phase 3 KEYNOTE-426 trial showed continued benefit with pembrolizumab plus axitinib for patients with advanced treatment-naïve clear cell renal cell carcinoma.

Appropriate monitoring of infusion-related reactions requires up-to-date knowledge of the latest criteria for adverse event management, health system policies, and protocols for reporting.

Axicabtagene ciloleucel delivered superior overall survival compared with standard of care in patients with early relapsed or refractory large B-cell lymphoma.

Patients with pretreated FGFR2/3-altered metastatic urothelial cancer derived a significant survival benefit with erdafitinib.

In the phase 2 DESTINY-PanTumor02 trial, trastuzumab deruxtecan elicited clinical activity across a range of HER2 expressing solid tumors.

Nirogacestat significantly reduced pain scores for patients with desmoid tumors.

Vorasidenib reduced the risk of progression or death by 61% compared with placebo for patients with grade 2 IDH-mutant glioma.

An analysis of patient-reported outcomes in the phase 3 RUBY trial supports dostarlimab use in patients with primary advanced or recurrent endometrial cancer.

Mirvetuximab soravtansine demonstrated an overall survival benefit in FRα-high, platinum-resistant ovarian cancer vs investigator's choice chemotherapy.

Patients with advanced-stage Hodgkin lymphoma who received nivolumab plus AVD experienced a 1-year estimated progression-free survival rate of 94% meeting the primary end point of the phase 3 SWOG S1826 trial.

Adjuvant osimertinib reduced the risk of death by 51% compared with placebo for patients with EGFR-mutated, stage IB, II, or IIIA non–small cell lung cancer.

Preoperative FOLFOX demonstrated noninferior efficacy outcomes vs preoperative chemoradiation in locally advanced rectal cancer.

Pembrolizumab before and after resection improves event-free survival outcomes for patients with early-stage NSCLC, according to findings from KEYNOTE-671.

Treatment with imetelstat elicited statistically significant and clinically meaningful improvements in transfusion independence among patients with lower-risk myelodysplastic syndrome.